“Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s154, https://doi.org/10.25251/skin.7.supp.154.